Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join


Sep 16, 2019 8:00 AM - Sep 17, 2019 5:00 PM

Kruisweg 495 , 2132 NA Hoofddorp , Netherlands

Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure


This conference will focus on two major developments currently affecting Paediatric Development: Innovative approaches to Drug Development and the impact of the current environment on the Regulatory and Research Infrastructure. You will gain critical insights from Regulators and leading industry experts about the latest scientific innovations and have the opportunity to engage in lively discussions with Paediatric Committee (PDCO) members and other industry experts involved in paediatric drug development. The patient experience will be voiced throughout the conference.

Featured topics

  • Leap in scientific innovation – how to address it for children
  • Future perspectives of the EU research landscape – IMI and beyond
  • Orphans and Paediatrics - where do we stand?

Who should attend?

  • Regulatory, clinical and drug development professionals from Health Authorities and Industry interested in paediatric drug development
  • Paediatricians, Representatives from Academia, Paediatric Societies and Networks, Patient Organisations
  • Employees from Clinical Research Organisations (CROs) involved in paediatric clinical trials
  • Any stakeholder interested in the development of better medicines for children

Learning objectives

  • Update participants on current paediatric regulatory requirements, scientific and operational successes and challenges
  • Provide overview of the way Brexit impacts Paediatric Development Strategy
  • Showcase latest developments with regards to innovation in how the paediatric studies are designed and conducted

Program Committee

  • Heidrun  Hildebrand
    Heidrun Hildebrand Paediatric Development Alliance Manager, Paediatric Medicine; Research and De
    BAYER, Germany
  • Mette  Due Theilade Thomsen, PhD
    Mette Due Theilade Thomsen, PhD CEO
    PIP Adviser, Denmark
  • Geneviève  Le Visage, PharmD, MSc
    Geneviève Le Visage, PharmD, MSc Head EU RA Policy and Liaison
    Novartis Pharma AG, Switzerland
  • Dimitrios  Athanasiou, MBA
    Dimitrios Athanasiou, MBA Patient Advocate
  • Martine  Dehlinger-Kremer, PhD
    Martine Dehlinger-Kremer, PhD VP Scientific Affairs, Pediatric SME, ICON Plc & President, EUCROF
  • Siri  Wang
    Siri Wang Scientific Director; PDCO delegate
    Norwegian Medical Products Agency, Norway

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.